Health Care & Life Sciences » Pharmaceuticals | High Tech Pharm Co. Ltd.

High Tech Pharm Co. Ltd. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
65,183
56,897
48,092
54,836
66,050
Cost of Goods Sold (COGS) incl. D&A
49,742
46,113
40,822
47,546
60,603
Gross Income
15,441
10,785
7,271
7,289
5,447
SG&A Expense
3,126
2,656
1,752
2,018
2,137
EBIT
12,282
7,887
5,398
5,176
3,271
Unusual Expense
-
65
-
-
-
Non Operating Income/Expense
32
1,321
2,296
1,294
728
Interest Expense
-
15
40
32
34
Pretax Income
13,142
9,929
8,261
6,684
2,551
Income Tax
2,687
2,094
1,717
1,403
451
Consolidated Net Income
10,455
7,835
6,544
5,280
2,100
Net Income
10,455
7,835
6,544
5,280
2,100
Net Income After Extraordinaries
10,455
7,835
6,544
5,280
2,100
Net Income Available to Common
10,455
7,835
6,544
5,280
2,100
EPS (Basic)
1,475.00
1,105.00
923.00
745.00
296.00
Basic Shares Outstanding
7
7
7
7
7
EPS (Diluted)
1,474.94
1,103.84
923.08
744.90
296.20
Diluted Shares Outstanding
7
7
7
7
7
EBITDA
13,365
8,807
6,208
5,861
3,872
Other Operating Expense
34
243
121
95
38
Non-Operating Interest Income
828
801
607
246
42

About High Tech Pharm Co.

View Profile
Address
280 Sinnae-ro
Eumseong-gun NC 27663
Korea, Republic Of
Employees -
Website http://www.htpharm.com
Updated 09/14/2018
High Tech Pharm Co., Ltd. engages in the manufacture and distribution of raw materials for injectable antibiotic products. Its products include imipenem, cilastatin sodium, blended imipenem-cilastatin sterile, meropenem, panipenem, and faropenem. The company was founded on September 1, 1998 and is headquartered in Eumseong, South Korea.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.